GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humanigen Inc (OTCPK:HGENQ) » Definitions » Shiller PE Ratio

Humanigen (Humanigen) Shiller PE Ratio : (As of May. 14, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Humanigen Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Humanigen Shiller PE Ratio Historical Data

The historical data trend for Humanigen's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humanigen Shiller PE Ratio Chart

Humanigen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Humanigen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Humanigen's Shiller PE Ratio

For the Biotechnology subindustry, Humanigen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Humanigen's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humanigen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Humanigen's Shiller PE Ratio falls into.



Humanigen Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Humanigen's E10 for the quarter that ended in Mar. 2023 is calculated as:

For example, Humanigen's adjusted earnings per share data for the three months ended in Mar. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-0.04/127.3478*127.3478
=-0.040

Current CPI (Mar. 2023) = 127.3478.

Humanigen Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201306 -19.600 98.518 -25.336
201309 -18.800 98.790 -24.235
201312 -10.000 98.326 -12.952
201403 -12.800 99.695 -16.350
201406 -11.900 100.560 -15.070
201409 -9.800 100.428 -12.427
201412 -11.800 99.070 -15.168
201503 -11.650 99.621 -14.892
201506 -7.300 100.684 -9.233
201509 -8.000 100.392 -10.148
201512 -15.850 99.792 -20.227
201603 -6.100 100.470 -7.732
201606 -13.150 101.688 -16.468
201609 -1.500 101.861 -1.875
201612 -1.689 101.863 -2.112
201703 -1.850 102.862 -2.290
201706 -2.050 103.349 -2.526
201709 -2.400 104.136 -2.935
201712 -1.050 104.011 -1.286
201803 -0.500 105.290 -0.605
201806 -0.100 106.317 -0.120
201809 -0.100 106.507 -0.120
201812 -0.100 105.998 -0.120
201903 -0.100 107.251 -0.119
201906 -0.150 108.070 -0.177
201909 -0.110 108.329 -0.129
201912 -0.090 108.420 -0.106
202003 -0.110 108.902 -0.129
202006 -0.790 108.767 -0.925
202009 -0.710 109.815 -0.823
202012 -0.630 109.897 -0.730
202103 -1.250 111.754 -1.424
202106 -1.200 114.631 -1.333
202109 -1.120 115.734 -1.232
202112 -0.480 117.630 -0.520
202203 -0.320 121.301 -0.336
202206 -0.430 125.017 -0.438
202209 -0.230 125.227 -0.234
202212 0.160 125.222 0.163
202303 -0.040 127.348 -0.040

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Humanigen  (OTCPK:HGENQ) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Humanigen Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Humanigen's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Humanigen (Humanigen) Business Description

Traded in Other Exchanges
N/A
Address
830 Morris Turnpike, 4th Floor, Short Hills, NJ, USA, 07078
Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. It has one segment, which is related to the development of pharmaceutical products.
Executives
Dale Chappell 10 percent owner C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Adrian Kilcoyne officer: Chief Medical Officer 533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
Cameron Durrant director 90, FAIRMOUNT ROAD WEST, CALIFON NJ 07830-3330
Edward P. Jordan officer: Chief Commercial Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
John Hohneker director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Yili Kevin Xie director C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Black Horse Capital Lp 10 percent owner C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Black Horse Capital Master Fund Ltd. 10 percent owner C/O OPUS EQUUM, INC., P.O. BOX 788, DOLORES CO 81323
Nomis Bay Ltd. 10 percent owner C/O EOM MANAGEMENT LTD., ANDREW'S PLACE, 51 CHURCH ST., 5TH FLOOR, HAMILTON D0 HM12
Cheryl Buxton director 533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
Cheval Holdings, Ltd. 10 percent owner P.O. BOX 309G, UGLAND HOUSE, GEORGETOWN, GRAND CAYMAN E9 KY1-1104
Black Horse Capital Management Llc 10 percent owner C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Robert G. Savage director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Rainer J. Boehm director C/O HUMANIGEN, INC., 1000 MARINA BOULEVARD, SUITE 250, BRISBANE CA 94005-1878
J Gregory Jester officer: Chief Financial Officer C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022

Humanigen (Humanigen) Headlines

From GuruFocus